Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Should l Buy AGIO?
Source: NASDAQ.COM
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 27.990
Low
25.00
Averages
36.14
High
62.00
Current: 27.990
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agios Submits sNDA for Accelerated Approval of Mitapivat in Sickle Cell Disease
- Clinical Trial Design: Agios' supplemental New Drug Application (sNDA) submission is based on an agreement with the FDA requiring a confirmatory clinical trial to demonstrate the clinical benefit of mitapivat in reducing transfusion burden in sickle cell disease, with approximately 159 patients expected to be enrolled over a 52-week period.
- Key Endpoint Setting: The primary endpoint of the confirmatory trial is the transfusion-free rate from Week 4 to Week 52, aiming to showcase mitapivat's effectiveness in lowering transfusion needs compared to placebo, reflecting its potential market value in sickle cell disease treatment.
- Clinical Data Support: In the RISE UP Phase 3 trial, mitapivat demonstrated significant improvements in hemoglobin concentration and reduced hemolysis, translating clinically into meaningful reductions in pain crises and hospitalizations, indicating its strong potential in treating sickle cell disease.
- Market Outlook: Agios expects to receive notice of the sNDA filing acceptance from the FDA in the third quarter of 2026, and if approved, mitapivat will become the first PK activator approved in the U.S., addressing the urgent need for new therapies among sickle cell disease patients.
See More
Agios Pharmaceuticals Presents New Data on Mitapivat at EHA 2026
- RISE UP Trial Results: At EHA 2026, Agios will present detailed efficacy and safety data from the RISE UP Phase 3 trial, demonstrating that patients treated with mitapivat showed significant improvements in average hemoglobin levels over 52 weeks and reduced markers of hemolysis, indicating the drug's potential in treating sickle cell disease.
- Long-term Efficacy Validation: In the ENERGIZE Phase 3 trial, 95% of patients opted to transition into the open-label extension period, showing that mitapivat treatment was well-tolerated and maintained clinically meaningful hemoglobin improvements for up to 127 weeks, further supporting its long-term use.
- Patient Feedback Improvement: Among patients receiving mitapivat, approximately 38.9% achieved a hemoglobin response during the double-blind period, with significant improvements in fatigue scores, highlighting the drug's positive impact on enhancing patients' quality of life.
- Global Academic Exchange: Agios will conduct 10 presentations and publications at EHA 2026, showcasing its research advancements in rare blood diseases, further solidifying its leadership position in the biopharmaceutical industry.
See More
Agios Pharmaceuticals Shares Rise 11.2% Following Strong Earnings Report
- Stock Surge: Agios Pharmaceuticals saw an 11.2% increase in shares this week, marking a positive turnaround for the year, reflecting market confidence in the company's future, particularly following the successful launch of Aqvesme.
- Significant Sales Growth: Aqvesme's sales reached $20.7 million in Q1 2026, a substantial increase from $8.7 million in the same quarter of 2025, which not only boosts overall revenue but also establishes a solid foundation for future market demand.
- New Drug Progress: Management confirmed alignment with the FDA, expecting to file for accelerated approval of mitapivat for sickle cell disease in Q2 2026, despite facing competition from Novo Nordisk, indicating strong market potential.
- Optimistic Future Outlook: Management is optimistic about the Phase 2 trial results for tebapivat, expected in the first half of 2026 for MDS and the second half for SCD, which will provide new momentum for the company's growth trajectory.
See More
Agios Pharmaceuticals Shares Surge 13.11% After Earnings Report
- Strong Earnings Report: Agios Pharmaceuticals reported a significant revenue increase from $8.7 million to $20.7 million year-over-year, demonstrating robust market performance for its new drug Aqvesme, highlighting the company's competitiveness in the anemia treatment sector.
- Widening Net Loss: Despite revenue growth, Agios' net loss expanded from $89 million to over $99 million, with a loss per share of $1.69, which, while exceeding analyst expectations, indicates ongoing investment in research and development.
- FDA Application Plans: Agios intends to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat to treat adult sickle cell disease, which, if approved, could further expand its market potential and enhance future revenue streams.
- Positive Market Reaction: Following a strong U.S. launch of Aqvesme, Agios' stock surged over 13% during trading, reflecting investor confidence in the company's future growth and strong market recognition of its products.
See More
Agios Pharmaceuticals Reports $21 Million Revenue in Q1
- Significant Revenue Growth: Agios Pharmaceuticals reported a revenue of $20.7 million in Q1, a 138% increase from $8.7 million in the same quarter last year, indicating strong market acceptance and sales potential for its new drug Aqvesme.
- FDA Approval for New Drug: Mitapivat has received FDA approval for the treatment of two blood disorders, further solidifying Agios's market position in the hematology sector and laying the groundwork for future revenue growth.
- Deepening Net Loss: Despite the revenue increase, Agios's net loss deepened to over $99 million in Q1, translating to a loss of $1.69 per share, which exceeded analyst expectations, yet the company remains optimistic about its future prospects.
- Future Development Plans: Agios plans to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat's use in treating adult sickle cell disease, which, if successful, will further expand its market share and product line.
See More
Agios Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Agios Pharmaceuticals reported net revenues of $20.7 million in Q1 2026, reflecting a 138% year-over-year increase, indicating strong market performance and growth potential, particularly driven by the new product AQVESME.
- Increase in AQVESME Prescriptions: As of March 31, the number of prescriptions for AQVESME reached 242, demonstrating early market acceptance in thalassemia treatment, which is expected to be a key driver of future growth for the company.
- sNDA Submission Plans: The company plans to submit an sNDA for mitapivat in sickle cell disease to the FDA in Q2, aiming for accelerated approval, a strategic move that will help expand market share and enhance competitive positioning.
- Cost Control Strategy: The CFO indicated that operating expenses for 2026 are expected to remain flat compared to 2025, demonstrating the company's commitment to strict cost management while expanding its business to ensure financial health and sustainable growth.
See More
Agios Submits sNDA for Accelerated Approval of Mitapivat in Sickle Cell Disease
- Clinical Trial Design: Agios' supplemental New Drug Application (sNDA) submission is based on an agreement with the FDA requiring a confirmatory clinical trial to demonstrate the clinical benefit of mitapivat in reducing transfusion burden in sickle cell disease, with approximately 159 patients expected to be enrolled over a 52-week period.
- Key Endpoint Setting: The primary endpoint of the confirmatory trial is the transfusion-free rate from Week 4 to Week 52, aiming to showcase mitapivat's effectiveness in lowering transfusion needs compared to placebo, reflecting its potential market value in sickle cell disease treatment.
- Clinical Data Support: In the RISE UP Phase 3 trial, mitapivat demonstrated significant improvements in hemoglobin concentration and reduced hemolysis, translating clinically into meaningful reductions in pain crises and hospitalizations, indicating its strong potential in treating sickle cell disease.
- Market Outlook: Agios expects to receive notice of the sNDA filing acceptance from the FDA in the third quarter of 2026, and if approved, mitapivat will become the first PK activator approved in the U.S., addressing the urgent need for new therapies among sickle cell disease patients.
See More
Agios Pharmaceuticals Presents New Data on Mitapivat at EHA 2026
- RISE UP Trial Results: At EHA 2026, Agios will present detailed efficacy and safety data from the RISE UP Phase 3 trial, demonstrating that patients treated with mitapivat showed significant improvements in average hemoglobin levels over 52 weeks and reduced markers of hemolysis, indicating the drug's potential in treating sickle cell disease.
- Long-term Efficacy Validation: In the ENERGIZE Phase 3 trial, 95% of patients opted to transition into the open-label extension period, showing that mitapivat treatment was well-tolerated and maintained clinically meaningful hemoglobin improvements for up to 127 weeks, further supporting its long-term use.
- Patient Feedback Improvement: Among patients receiving mitapivat, approximately 38.9% achieved a hemoglobin response during the double-blind period, with significant improvements in fatigue scores, highlighting the drug's positive impact on enhancing patients' quality of life.
- Global Academic Exchange: Agios will conduct 10 presentations and publications at EHA 2026, showcasing its research advancements in rare blood diseases, further solidifying its leadership position in the biopharmaceutical industry.
See More
Agios Pharmaceuticals Shares Rise 11.2% Following Strong Earnings Report
- Stock Surge: Agios Pharmaceuticals saw an 11.2% increase in shares this week, marking a positive turnaround for the year, reflecting market confidence in the company's future, particularly following the successful launch of Aqvesme.
- Significant Sales Growth: Aqvesme's sales reached $20.7 million in Q1 2026, a substantial increase from $8.7 million in the same quarter of 2025, which not only boosts overall revenue but also establishes a solid foundation for future market demand.
- New Drug Progress: Management confirmed alignment with the FDA, expecting to file for accelerated approval of mitapivat for sickle cell disease in Q2 2026, despite facing competition from Novo Nordisk, indicating strong market potential.
- Optimistic Future Outlook: Management is optimistic about the Phase 2 trial results for tebapivat, expected in the first half of 2026 for MDS and the second half for SCD, which will provide new momentum for the company's growth trajectory.
See More
Agios Pharmaceuticals Shares Surge 13.11% After Earnings Report
- Strong Earnings Report: Agios Pharmaceuticals reported a significant revenue increase from $8.7 million to $20.7 million year-over-year, demonstrating robust market performance for its new drug Aqvesme, highlighting the company's competitiveness in the anemia treatment sector.
- Widening Net Loss: Despite revenue growth, Agios' net loss expanded from $89 million to over $99 million, with a loss per share of $1.69, which, while exceeding analyst expectations, indicates ongoing investment in research and development.
- FDA Application Plans: Agios intends to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat to treat adult sickle cell disease, which, if approved, could further expand its market potential and enhance future revenue streams.
- Positive Market Reaction: Following a strong U.S. launch of Aqvesme, Agios' stock surged over 13% during trading, reflecting investor confidence in the company's future growth and strong market recognition of its products.
See More
Agios Pharmaceuticals Reports $21 Million Revenue in Q1
- Significant Revenue Growth: Agios Pharmaceuticals reported a revenue of $20.7 million in Q1, a 138% increase from $8.7 million in the same quarter last year, indicating strong market acceptance and sales potential for its new drug Aqvesme.
- FDA Approval for New Drug: Mitapivat has received FDA approval for the treatment of two blood disorders, further solidifying Agios's market position in the hematology sector and laying the groundwork for future revenue growth.
- Deepening Net Loss: Despite the revenue increase, Agios's net loss deepened to over $99 million in Q1, translating to a loss of $1.69 per share, which exceeded analyst expectations, yet the company remains optimistic about its future prospects.
- Future Development Plans: Agios plans to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat's use in treating adult sickle cell disease, which, if successful, will further expand its market share and product line.
See More
Agios Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Agios Pharmaceuticals reported net revenues of $20.7 million in Q1 2026, reflecting a 138% year-over-year increase, indicating strong market performance and growth potential, particularly driven by the new product AQVESME.
- Increase in AQVESME Prescriptions: As of March 31, the number of prescriptions for AQVESME reached 242, demonstrating early market acceptance in thalassemia treatment, which is expected to be a key driver of future growth for the company.
- sNDA Submission Plans: The company plans to submit an sNDA for mitapivat in sickle cell disease to the FDA in Q2, aiming for accelerated approval, a strategic move that will help expand market share and enhance competitive positioning.
- Cost Control Strategy: The CFO indicated that operating expenses for 2026 are expected to remain flat compared to 2025, demonstrating the company's commitment to strict cost management while expanding its business to ensure financial health and sustainable growth.
See More
